

Neuland Laboratories Limited 11th Floor, (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

April 22, 2022

To BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001

Scrip Code: 524558

To The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai - 400 001

Scrip Code: NEULANDLAB; Series: EQ

Dear Sirs,

Sub: Initial Disclosure for FY 2022-23

Ref: SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

("SEBI Circular")

Please find enclosed herewith Initial Disclosure under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 ("SEBI Circular") in respect of Fund raising by issuance of Debt Securities by Large Entities, for FY 2022-23.

This is for your information and records.

Thanking You,

Yours faithfully,

For Neuland Laboratories Limited

HYDERABAL

Sarada Bhamidipati,

Company Secretary

Encl: As Above

Initial Disclosure to be made by an entity identified as a Large Corporate (To be submitted to the Stock Exchange(s) within 30 days from the beginning of the FY)

April 22, 2022

S.No.	Particulars	Details
1	Name of the company	Neuland Laboratories Limited
2	CIN	L85195TG1984PLC004393
3	Outstanding borrowing of company as on 31st March/ 31st December, as applicable (in Rs cr)	Rs.112.78 Crs
4	Highest Credit Rating During the previous FY along with name of the Credit Rating Agency	A- Stable outlook (India Ratings & Research Private Limited)
5	Name of Stock Exchange [#] in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	BSE Limited

#In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

We confirm that we are **not** a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

For Neuland Laboratories Limited

Sarada Bhamidipati_

Company Secretary

+91 40 6761 1600

Chief Financial Officer

+91 40 6761 1600